Chugai Pharma Manufacturing Co., Ltd. is a member of the Chugai Group and is responsible for manufacturing functions.
In this interview, we focus on FJ2, a synthesis API manufacturing facility for small and mid-size molecule drugs in which we were involved from the concept design.
FJ2 was awarded the 2023 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE).
photos from corporate site of Chugai Pharma Manufacturing Co., Ltd.
Company Information
Name | Chugai Pharma Manufacturing Co., Ltd |
---|---|
Establishment | May 2006 |
Capital | 80 million yen |
Representative | Kenji Kamada, President and Representative Director |
Number of employees | 1508 (as of December 31, 2021) |
Business | Manufacture of pharmaceutical products |
-
- Daisuke Hirasawa
- Digital & Engineering Dept.
SPECIALIST
ENGNEERING
-
- Kiminori Matsuura
- GROUP MANAGER
MANUFACTURING GROUP 2
Positioning of the FJ2 Project
- CM Plus
- Congratulations on receiving the Facility of the Year Award from ISPE.
Although our assistance was limited to conceptual design, engineering company selection support, and on-site building structure and piping welding management support, we are delighted that the project we were involved in has been recognized internationally.
What is the positioning and significance of the FJ2 project for Chugai?
Hirasawa
- Chugai’s strength is in biopharmaceuticals and antibody drugs, but we also position small and mid-size molecule drugs as one of our major pillars, and we decided to construct FJ2 as an important infrastructure to accelerate their development and increase their supply capacity. Please refer to the press release.
https://www.chugai-pharm.co.jp/english/news/detail/20190424170001_617.html?year=2019&category=
- CM Plus
- At the Fujieda plant, the construction of FJ1, then FJ2, and now FJ3 is underway.
At which phase of the development stage will the products handled in FJ2 be?
Hirasawa
- FJ2 corresponds to the Phase 1 to 2 of clinical trials. Our major strategy is to manufacture products at Chugai consistently and in line with the clinical trial development phase; Phase 1~2 are for FJ1 and 2, and Phase 3 to early commercial products are for FJ3.
In addition, many of the drugs Chugai manufactures are highly active, and it is difficult to outsource manufacturing to outside CMOs, etc. This was also behind our decision that it would be advantageous in terms of further acceleration of development if we could consistently handle the manufacturing in-house.
- CM Plus
- Hence you make a strategic decision after considering the possibility of outsourcing, do you? The recent trend in pharmaceutical manufacturing is to outsource to CDMOs, but we understand that you are emphasizing the advantages of doing everything from development to manufacturing in-house.
Matsuura
- Chugai’s development products have become very active, and outsourcing was almost impossible. Recently, original drug manufacturers have been outsourcing their development and manufacturing to CDMOs. The contract market is booming, but outsourcing the supply of APIs in the initial phase will still slow down the process. The earlier the initial phase is, the faster we can supply the drug substance if we manufacture it in-house.
- CM Plus
- That makes sense. So, you are aiming for a facility that can handle everything from development to actual production, including the FJ3 project that we are currently assisting with?
Hirasawa
- Yes, FJ3 is positioned as a so-called launch plant that can handle initial commercial production.
Matsuura
- We started construction of FJ1 around 2003, but 20 years have passed since then, and the quality of our development products has changed in the FJ2 project. The high potency I mentioned earlier and the need to cover small and mid-size molecule are now required, and FJ2 reflects these changes.
Hirasawa
- When we were proceeding with the conceptual design of FJ2, few people knew anything about facility construction, and we were starting from a question “how can we proceed?”
- CM Plus
- Thank you for consulting with CM Plus on that occasion. Being involved in your important project during the conceptual design phase has been a pleasure.
We heard Mr. Hirasawa’s presentation at the recent seminar hosted by Business Engineering Corporation. A facility with a containment performance of 0.05㎍/m3 or less is a rarity, even on a global scale.
Hirasawa
- Now that the project is completed, we can say that we have achieved it, but at the beginning of the project, many people thought it would be difficult.
- CM Plus
- At the beginning of the study, we also expressed our opinion that it would be difficult. We apologize for our rudeness and pay our respects to your company for clearing this challenging standard.
At the kick-off meeting for FJ2, nine years ago, Mr. Hirasawa explained the design concept of the containment facility, and we identified the tasks for each manufacturing process and considered appropriate containment measures for each task, and through repeated examination and verification, we were finally able to overcome the wall of 0.05μg/m3.
Hirasawa
- The project had many difficulties, but we believe all sorted. As we mentioned at the seminar the other day, thoroughly examining the facilities in the early stages, when there is a high degree of flexibility is essential. we think the fact that we were able to work on the concept design with CM Plus, who had knowledge in the early stages and shared the same final goal, has led us to where we are today.
- CM Plus
- We are very glad to know that.
概念設計時 平面図
概念設計時 断面図
About ISPE’s Facility of the Year Awards
- CM Plus
- Talking about this facility, how did Chugai respond to receiving the Facility of the Year Awards from ISPE?
Matsuura
- The response was beyond our expectations, including from companies related to the Chugai Group as a whole. We also received attention from within the company as well.
Hirasawa
- We had more opportunities to make presentations after receiving the award, and I began to receive feedback from both inside and outside the company, even from people we didn’t know, such as, “This is a good project.”
- CM Plus
- How was the award ceremony?
Matsuura
- The award ceremony was spectacular, and all the Chugai members seemed to feel a sense of accomplishment as they were honored as winners in front of about 500 people in attendance.
Hirasawa
- As a Winner, we presented the FJ2 project to the participants during the conference, which was a valuable opportunity for us to communicate the project to the outside.
- CM Plus
- We heard that the presentation was excellent. We think it was an effective way for your company to communicate the FJ2 project to the outside. As a Japanese, we feel proud that Mr. Hirasawa was able to play an active role in a place that is attracting worldwide attention. We would like to see other Japanese projects challenge FOYA more aggressively, but there are still very few. We think it is partly because Japanese people are not good at appealing to the outside and partly because they don’t want to put information outside the company in the first place.
Matsuura
- Indeed, plants of Japanese original drug manufacturers are rarely shown to the outside.
We assume that we are gradually changing how we show and present information to the outside.
Hirasawa
- We were also fortunate to have a supervisor, a plant manager, and a department manager who understood our decision to entry the award. With their approval, we were able to actively submit more products.
- CM Plus
- This is Chugai’s corporate culture. As you have stated in your policy, you respect “employee initiative” and “taking on challenges”.
Hirasawa
- We entered the competition with the understanding of the people around me, and at that point, I just wanted to keep it as a memento. We were deeply moved by the fact that the project was selected for the award, and what we had accomplished was conveyed to various people within the company. The reverberations spread like ripples spreading from a stone thrown into the water.
- CM Plus
- A single stone thrown into the water triggered a ripple of positive trends spreading further within the company and beyond.

Why you invited a Construction Management (CM) Company? And why that was CM Plus?
- CM Plus
- Could you please explain why you invited a CM company in the FJ2 project?
Hirasawa
- One of our objectives was to ensure transparency. The idea was to place the order transparently, which would allow us to explain the project to shareholders and other interested parties. If we entrusted the project to a particular order, it would not be fair to our clients. To ensure transparency that can be explained, we thought it necessary to obtain quotes from other companies and make a selection.
- CM Plus
- Recently, we have seen an increase in customers who think this way in Japan. They are required to be accountable to internal and external parties. Suppose the conventional method of placing a lump-sum order from design to construction with a single company’s particular order is used. In that case, accountability cannot be fulfilled, so they have established a policy of placing orders after creating a competitive environment and making selections. They will likely use us, CM Plus, in that case.
Hirasawa
- The FJ2 project was the first large-scale construction of an API manufacturing building since FJ1, completed about 20 years ago, so we hired a consulting company to facilitate the initial phase.
Matsuura
- We still remember that at the time, we could not estimate how much the project would cost.
- CM Plus
- We are honored to work with you. We are very good at taking a project from its initial formless state, giving it shape, and narrowing down the plan while presenting a rough cost estimate.
What made you choose CM Plus from among many CM companies?
Hirasawa
- We selected CM Plus because of its strengths in both buildings and process equipment.
Matsuura
- At the time, we searched the Internet for CM companies, but only CM Plus offered services that included production equipment.
- CM Plus
- Thank you very much. We are proud of the fact that we can provide design services including process equipment. There are many architectural design firms and CM companies in Japan, but most of them are architectural companies. We believe that we are a unique design firm and CM firm that has the DNA of engineering and can design facilities centered on process equipment.
- CM Plus
- How was it hiring CM Plus? We would like to have your frankly opinion about our strengths and an area for improved.
Hirasawa
- We feel that the level of responsibility and the results they delivered on the work we requested for the FJ2 project are worthy of recognition. We also appreciated the flexible and timely response to our project requirements during the work period. You contributed to the stable progress of the project.
To proceed with the project, we had to involve many people. Where our information was not sufficient to gain understanding, you provided us with a wealth of information, which enabled us to proceed quickly and with a sense of unity among all parties involved.
Matsuura
- We are glad that you were involved in the project from the initial stages to the inspection at the time of construction and that you could confirm and make various proposals based on your understanding of the FJ2 concept. Since you were involved in the project from the concept design stage, you knew the concept and background of FJ2, so you could chatter and give us precise support at the points where we needed it.
- CM Plus
- Thank you for your appreciation. We are delighted that we were able to help you execute your project.

- CM Plus
- Thank you for the opportunity to interview you today.

Plot 1: About the FOYA award trophy.
- CM Plus
- After receiving the trophy at the awards ceremony…

- Hirasawa
- After receiving the award at the ceremony, we initially thought of sending it directly to the Fujieda Plant,
after consulting with the people involved, it was decided that showing them at each plant would be better. We chose to display them first at the Ukima Plant, then at the Utsunomiya Plant, and finally at the Fujieda Plant.
At the time of the interview, we were fortunate enough to see and photograph the actual product after it had been displayed at the Fujieda Plant after its touring trip.
Plot 2:

After the interview, our president, Mr. Suekane, gave a course titled “Project Management for Construction of a Pharmaceutical Factory”. Please refer to our book “How to Build a Pharmaceutical Plant” for more information on project execution.
Note: The information included in the interview article is as of the time of the interview.
Related Services
Related Contents
Engineering testimonials
-
Engineering Indonesia Factory Construction Project: Meeting Strict Design Concepts and Ensuring Safety and Quality Within Budget as a Globally Compliant Factory Takasago International Corporation
-
Engineering Japan's first containerized data center to support cloud computing services was built in Matsue City, Shimane Prefecture. Internet Initiative Japan Inc. (IIJ)
-
Engineering As a partner for the new location project because of its knowledge of the pharmaceutical industry, technical capabilities, and flexibility. From conceptual design to construction, we managed costs and schedules thoroughly. Iwata Label Co., Ltd. (currently IL Pharma Packaging Co., Ltd.)